64x Bio develops manufacturing platforms designed to improve the scalability and economics of advanced therapy production. The company's core offering, VectorSelect™, combines massively parallelized screening with computational analysis to optimise production cell lines and manufacturing processes. This approach enables partners to develop high-yield production systems tailored to their specific therapeutic contexts.
The company's product suite includes the AAV Apex Suite, a specialised line for gene therapy manufacturing built on suspension-adapted HEK293 cell lines optimised for transient transfection. 64x Bio positions its technologies as applicable across multiple therapeutic modalities - gene therapy, cell therapy, and biologics - rather than limited to a single application.
64x Bio operates through licensing and collaboration partnerships, allowing external organisations to access and implement its cell line development and process optimisation capabilities. The company's technical foundation rests on high-throughput experimentation, computational insights, and process development expertise targeted at the manufacturing bottlenecks that constrain advanced therapy scale-up.
